Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 18/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 14/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3473963 | 0.86 | EPHX2 (1.00) | EPHX2CYP2C9KDM4E | |
| SCHEMBL2258419 | 0.82 | EPHX2 (0.91) | EPHX2CYP2C9 | |
| SCHEMBL2260526 | 0.82 | EPHX2 (1.00) | EPHX2CYP2C9 | |
| SCHEMBL2262439 | 0.82 | EPHX2 (0.78) | EPHX2CYP2C9 | |
| SCHEMBL2259136 | 0.81 | EPHX2 (0.76) | EPHX2CYP2C9 | |
| SCHEMBL2258231 | 0.81 | EPHX2 (0.80) | EPHX2CYP2C9 | |
| SCHEMBL2260336 | 0.81 | EPHX2 (0.80) | EPHX2CYP2C9 | |
| SCHEMBL2261854 | 0.81 | EPHX2 (1.00) | EPHX2CYP2C9 | |
| SCHEMBL2262275 | 0.80 | EPHX2 (0.89) | EPHX2CYP2C9 | |
| SCHEMBL2790708 | 0.80 | EPHX2 (1.00) | EPHX2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2240025-A1 | NOVEL sEH INHIBITORS AND THEIR USE | GlaxoSmithKline LLC (US) | 2010-10-20 | — | — | EP | claimed |
| WO-2009097475-A1 | NOVEL sEH INHIBITORS AND THEIR USE | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-06 | — | — | WO | claimed |
| US-20100311775-A1 | Novel sEH Inhibitors and Their Use | SMITHKLINE BEECHAM CORPORATION (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100311775-A1 | Novel sEH Inhibitors and Their Use | SMITHKLINE BEECHAM CORPORATION (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100311775-A1 | Novel sEH Inhibitors and Their Use | SMITHKLINE BEECHAM CORPORATION (US) | 2010-12-09 | — | — | US | disclosed |
| EP-2240025-A1 | NOVEL sEH INHIBITORS AND THEIR USE | GlaxoSmithKline LLC (US) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009097475-A1 | NOVEL sEH INHIBITORS AND THEIR USE | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311775-A1 | Novel sEH Inhibitors and Their Use | EPHX1, NCEH1, FAH | EPHX2 4/4885CYP2C9 160/4885KDM4E 1350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.